INDP Indaptus Therapeutics: Forward P/S Multiple
The strategic vector of Indaptus Therapeutics (INDP) is focused on creating cancer treatment methods that are resilient to macro shocks. The business's forward P/S demonstrates progress on this path, where captures a new level. The complexity of utilizing killed bacteria in therapy serves as an obstacle; however, experienced management effectively controls cash flow, ensuring the stability of current clinical trials.
Metric breakdowns and analytics for Indaptus Corp (INDP)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital Indaptus Therapeutics|INDP - Long-Term Debt to Capital|Short-Term Debt to Equity Indaptus Therapeutics|INDP - Company Aggregate Indebtedness|Debt to Book Value Indaptus Corp|INDP - Amount of Long-Term Liabilities|Company Current Liabilities Indaptus Therapeutics|Quick Liquidity indaptusrx.com
- business earnings and investment ratios data:
INDP - Net Financial Result|Future Profit Indaptus Therapeutics|INDP - Company Value to Net Income|Projected Price to Earnings Indaptus|INDP - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Indaptus Corp|INDP - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Indaptus Therapeutics|INDP - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months indaptusrx.com|INDP - Earnings per share increase in current year|Earnings growth forecast for next year Indaptus Therapeutics
- sales and revenue indicators:
Fundamental valuation:Indaptus Therapeutics, Inc. (INDP)
The effectiveness of Indaptus Therapeutics (INDP) immunotherapy is limited by geopolitical barriers that slow global drug registration and constrain revenue growth. The ratio of market capitalization to projected sales volume allows for a real-time assessment of market expectations regarding asset monetization, while the future P/S multiple serves as an indicator of the company's overvaluation amid regulatory risks and stagnant clinical trials.
Competing companies
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio ADMA Corp ADMA|Protagonist Therapeutics (PTGX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue IMVT|KNSA (Kiniksa) - Forward P/S Multiple|Market Cap to Projected Revenue GRFS (Grifols SA)|Forward P/S Multiple ADPT|Forward P/S Multiple Celldex Corp (CLDX)|Price-to-Projected Revenue Ratio Aurinia Pharmaceuticals AUPH|BCRX (biocryst.com) - Future Price to Revenue|VERA: Forward Price-to-Revenue Multiple|Dianthus Therapeutics Inc - Price to Expected Revenue Ratio|PHVS (Pharvaris Corp) - Forward Price-to-Revenue Multiple|AbCellera Corp (ABCL) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Tourmaline Bio, Inc.|precigen.com (PGEN) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple PHAR (Pharming Group)|NKTR (Nektar Therapeutics Inc) - Forward Price to Sales|Upstream Bio Corp - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ZBIO (Zenas Corp)|Immunome, Inc. - Forward P/S Multiple|Forward Price to Sales GOSS (gossamerbio.com)|KALV: Forward P/S Multiple|Market Cap to Future Revenue Ratio Septerna, Inc. (SEPN)|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals Inc|SVRA: Forward Price to Sales|Forward P/S Multiple RIGL|Forward P/S Multiple anaptysbio.com (ANAB)|Price-to-Projected Revenue Ratio Astria Therapeutics, Inc. ATXS|ENGN (enGene Holdings Inc) - Future Price to Revenue|RAPT Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aerovate Therapeutics Inc|ACRS (Aclaris Therapeutics) - Forward Price-to-Revenue Multiple|kyvernatx.com (KYTX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple TLSA|CABA (Cabaletta Bio Inc.) - Price to Expected Revenue Ratio|Forward P/S Multiple VTYX|Market Cap to Expected Sales Ratio Theratechnologies, Inc|Forward P/S Multiple AVTX (Avalo Therapeutics, Inc)|ELDN - Forward Price-to-Revenue Multiple|AGEN - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Climb Bio Inc. CLYM|ZURA: Forward P/S Multiple|ATYR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Adagene Inc|Market Cap to Projected Revenue IMA (Ikena Oncology, Inc.)|Forward P/S Multiple STTK|equilliumbio.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Connect Biopharma Holdings Limited CNTB|IMUX (Immunic Therapeutics) - Future Price to Revenue|ATRA - Price-to-Projected Revenue Ratio|Future Price to Revenue IFRX|XFOR: Forward P/S Multiple|Adicet Bio, Inc. - Forward Price to Sales|CELU (Celularity Inc) - Forward P/S Multiple|Forward P/S Multiple INmune Bio Corporation|Price-to-Projected Revenue Ratio Barinthus Biotherapeutics (BRNS)|KZR (kezarlifesciences.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio SAB Biotherapeutics, Inc. SABS|AKTX - Forward Price-to-Revenue Multiple|Enlivex Therapeutics, Ltd. - Forward P/S Multiple|QTTB - Forward P/S Multiple|GOVX (GeoVax Labs, Inc.) - Forward Price-to-Revenue Multiple|edesabiotech.com - Forward Price to Sales|IBIO (iBio) - Forward P/S Multiple|Carisma Tx (CARM) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio XTL Biopharmaceuticals, Ltd. (XTLB)|Forward Price-to-Revenue Multiple boltbio.com BOLT|Price-to-Projected Revenue Ratio HCW Biologics HCWB|APVO - Forward Price-to-Revenue Multiple|AIM: Forward Price-to-Revenue Multiple|ADTX - Forward P/S Multiple|GRI Bio Corp (GRI) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue XRTX|HIND (Vyome Holdings Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio revbiosciences.com REVB|Forward P/S Multiple SCNI|Market Cap to Expected Sales Ratio calcimedica.com|Price-to-Projected Revenue Ratio Affimed N.V. AFMD|ALLK: Market Cap to Projected Revenue|HOOKIPA - Forward P/S Multiple|IGMS (IGM Biosciences, Inc.) - Market Cap to Projected Revenue|ITOS: Forward P/S Multiple|Ocean Biomedical Inc (OCEA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Third Harmonic Bio Inc - Future Price to Revenue
